More and more people are experiencing HIV drug resistance following treatment failure. Each switch of medication and each interruption of therapy will have a cumulative effect on the level and the breadth of cross-resistance. In order to restrict therapeutic failure and to save future treatment options, it is very important to use the maximum information available to select optimal treatments for each individual at each treatment switch.

PHENOSCRIPT™ provides a simple and direct measure of the antiretroviral susceptibility of a virus reconstructed from a plasma sample using an original technique, which is particularly rapid requiring only 7 days of laboratory time.

Through the use of clinically relevant cut-offs for 8 antiretrovials (more than any other resistance test), PHENOSCRIPT™ helps your treatment provider to take the best decisions to preserve future therapeutic options and thus limit the development of extensive cross-resistance.

Because PHENOSCRIPT™ provides a direct and quantitative measure of the susceptibility of the virus it can be used in combination with data about the levels of drugs in your plasma to optimise both the combination and the dose of active treatments.

You should discuss with your doctor the potential advantages a phenotypic resistance test could offer you.

Principle of the PHENOSCRIPT™ assay
The PHENOSCRIPT™ report
Important parameters
Comparison with other commercially available tests

To order PHENOSCRIPT™